Genital Dysplasia in Women Infected with Human Immunodeficiency Virus

References

1. ↵
   Ahdieh L, Munoz A, Vlahov D, Trimble CL, Timpson LA, Shah K. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000; 151: 1148–57.

   OpenUrlAbstract/FREE Full Text
2. ↵
   Garzetti GG, Ciavattini A, Butini L, Vecchi A, Montroni M. Cervical dysplasia in HIV-seropositive women: role of human papillomavirus infection and immune status. Gynecol Obstet Invest 1995; 40: 52–6.

   OpenUrlPubMedWeb of Science
3. Moscicki AB, Ellenberg JH, Vermund SH, et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 2000; 154: 127–34.

   OpenUrlCrossRefPubMedWeb of Science
4. Shah K, Solomom L, Daniel R, Cohn S, Lahov D. Comparison of PCR and hybrid capture methods for detection of human papillomavirus in injection drug-using women at high risk of human immunodeficiency virus infection. J Clin Microbiol 1997: 517–9.
5. Six C, Heard I, Bergeron C, et al. Comparative prevalence, incidence and short-term prognosis of cervical squamous intraepithelial lesions amongst HIV-positive and HIV-negative women. AIDS 1998; 12: 1047–56.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   Ellerbrock T, Chiasson M, Bush BA, Sun X, Wright T, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 200; 283: 1031–7.

   OpenUrl
7. ↵
   Maiman M, Fruchter RG, Clark M, Arrastia CD, Matthews R, Gates EJ. Cervical cancer as an AIDS-defining illness. Obstet Gynecol 1997; 89: 76–80.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   Petry KU, Scheffel D, Bode U, et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 1994; 57: 836–40.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   Ahr A, Scharl A, Lutke K, Staszewski S, Kacer PZ, Kaufmann M. Cervical intraepithelial neoplasia in human immunodeficiency virus-positive patients. Cancer Detect Prev 2000; 24: 179–85.

   OpenUrlPubMed
10. ↵
    Schafer A, Friedmann W, Mielke M, Schwartlander B, Koch MA. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 1991; 164: 593–9.

    OpenUrlPubMedWeb of Science
11. ↵
    Heard I, Tassie JM, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load. Obstet Gynecol 2000; 96: 403–9.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    Fruchter RG, Maiman M, Sedlis A, Bartley L, Camilien L, Arrastia CD. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996; 87: 338–44.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    Maiman M. Management of cervical neoplasia in human immunodeficiency virus-infected women. J Natl Cancer Inst Monogr 1998; (23): 43–9.
14. ↵
    Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12: 1459–64.

    OpenUrlCrossRefPubMedWeb of Science
15. Fiore T, Chapman S, Perry K, Stenzel M, Gormley J, Cu-Uvin S. Prevalence of cervical dysplasia in a cross-sectional study of HIV positive women (abstract). Program and Abstracts of the 13th International AIDS Conference; 2000 July 9–14; Durban, South Africa. Abstract MoPeB2241.
16. Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184: 547–51.

    OpenUrlAbstract/FREE Full Text
17. ↵
    Orlando G, Fasolo MM, Schiavini M, Signori R, Cargnel A. Role of highly active antiretroviral therapy in human papillomavirus-induced genital dysplasia in HIV-1-infected patients. AIDS 1999; 13: 424–5.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    Duerr A, Shah K, Klien R, Cu-Uvin S. The effect of highly active antiretroviral therapy (HAART) on cervical dysplasia and HPV infection among HIV-infected women. Program and abstracts of the 12th World AIDS Conference; 1998 June 29-July 3; Geneva, Switzerland. Abstract 60289.
19. ↵
    A guide to the clinical care with women with HIV/AIDS, 1st ed. Rockville (MD): US Department of Health and Human Services; 2001. p. 157. Available at URL: http://hab.hrsa.gov/womencare.htm
20. ↵
    Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Rockville (MD): US Department of Health and Human Services; 2000.
21. ↵
    Kaplan J, Hanson, Dworkin M, Frederick T, Jones J, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30: S5–S14.
22. ↵
    Dorrucci M, Suligoi B, Serraino D, et al. Incidence of invasive cervical cancer in a cohort of HIV-seropositive women before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26: 377–80.
23. ↵
    Sieg SF, Mitchem JB, Bazdar DA, Lederman MM. Close link between CD4+ and CD8+ T cell proliferation defects in patients with human immunodeficiency virus disease and relationship to extended periods of CD4+ lymphopenia. J Infect Dis 2002; 185: 1401–16.

    OpenUrlAbstract/FREE Full Text
24. ↵
    Sun X, Kuhn L, Ellerbrock T, Chiasson M, Bush T, Wright T. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 1343–86.

    OpenUrlCrossRefPubMedWeb of Science
25. Ho GYF, Burk RD, Klien S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 1365–71.

    OpenUrlAbstract/FREE Full Text
26. ↵
    Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynecol Oncol 2000; 79: 294–9.

    OpenUrlCrossRefPubMedWeb of Science
27. ↵
    Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24: 475–82.
28. ↵
    Anderson K, Mitchell J. Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. Arch Intern Med 2000; 160: 3114–20.

    OpenUrlCrossRefPubMedWeb of Science